Browse All

Current Filters

CLEAR FILTER x

TITLE

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Montalban, Xavier   Cohen, Jeffrey   Morrow, Sarah   Li, Jun   Carr, David   Pearce, Gregory   Solonets, Maria   Abeyewickreme, Anil   de Seze, Jérôme   Nakahara, Jin   Wiendl, Heinz   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials 2  

Topic:Multiple Sclerosis  

Program Number:P9.006  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Department of Neurology/Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, calgary, AB, Canada  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  IQVIA RDS GmbH, Frankfurt, Germany, Germany  Novartis Pharmaceuticals UK Ltd, London, United Kingdom, London, United Kingdom  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Klinik für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Freiburg, Germany, Freiburg im Breisgau, Germany  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  

Pregnancy and Infant Outcomes in Women With Relapsing Multiple Sclerosis Following Exposure to Ofatumumab: Latest Evidence From the PRIM Study

Author:Bove, Riley   Stoll, Sharon   Dobson, Ruth   Amato, Maria   Kharat, Vineetkumar   Abeyewickreme, Anil   Jehl, Valentine   Kramarikova, Ivana   Yamout, Bassem   Krysko, Kristen   Vukusic, Sandra   Hellwig, Kerstin   

Session Name:P11: Multiple Sclerosis: Sex and Gender Informed Neurology  

Topic:Multiple Sclerosis  

Program Number:P11.002  

Author Institution:UCSF Weill Institute for Neurosciences, San Francisco, Berkeley, CA  Advocare, Stoll Medical Group, Philadelphia, Philadelphia, PA  Wolfson Institute of Population Health, London, United Kingdom  University of Florence, Florence, Italy  Novartis Pharmaceuticals Corporation, NJ  Novartis Pharmaceuticals UK Ltd., London, United Kingdom  Novartis Pharma AG, Basel, Switzerland  Harley Street Medical Center, Abu Dhabi, United Arab Emirates  St. Michael's Hospital, Toronto, ON, Canada  Lyon University Hospital, Lyon, France  St. Josef Hospital/Ruhr University Bochum, Bochum, Germany